Skip to main content


Log in

Role of Stereotactic Radiation Therapy in Operable and Inoperable Early-Stage Non-small Cell Lung Cancer

  • Lung Cancer (TA Leal and N Sethakorn, Section Editors)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Radiation therapy is becoming an increasingly important part of non-small cell lung cancer (NSCLC) management. Approximately 60% of all cancer patients require radiation therapy (RT) as part of their treatment. For lung cancer, this number is even higher, reaching approximately 77% of all patients, from radical to palliative modalities of RT. This percentage may even be underestimated, as it may not account for the more recent use of RT in oligometastatic lung cancer patients. Thus, we can estimate that each year there will be approximately 21,890 new lung cancer patients in the USA requiring RT. These numbers are expected to continue to rise, as lung cancer radiation techniques continue to improve. There is growing interest in determining the best treatment options for early-stage NSCLC patients. There is well-established data showing the benefit of RT for inoperable patients, and more recent encouraging data even in operable patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

    Article  Google Scholar 

  2. Office of the Surgeon General (US), Office on Smoking and Health (US). The health consequences of smoking: a report of the surgeon general [Internet]. Atlanta: Centers for Disease Control and Prevention (US); 2004 [cited 2022 Jul 16]. Available from:

  3. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.

    Article  Google Scholar 

  4. Mohan G, Ayisha Hamna TP, Jijo AJ, Saradha-Devi KM, Narayanasamy A, Vellingiri B. Recent advances in radiotherapy and its associated side effects in cancer—a review. J Basic Appl Zool. 2019;80:14.

    Article  Google Scholar 

  5. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60:615–22. discussion 622-623.

  6. Haasbeek CJA, Senan S, Smit EF, Paul MA, Slotman BJ, Lagerwaard FJ. Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. Oncologist. 2008;13:309–19.

    Article  Google Scholar 

  7. Abreu CECV, Ferreira PPR, de Moraes FY, Neves WFP Jr, Gadia R, de Andrade Carvalho H. Stereotactic body radiotherapy in lung cancer: an update. J Bras Pneumol. Sociedade Brasileira de Pneumologia e Tisiologia. 2015;41:376–87.

  8. • Videtic GMM, Donington J, Guiliani M, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017. This reference is important because was first consensus did by thoracic surgeons and radiation oncologist about SBRT for early-stage non-small cell lung cancer

  9. Schneider BJ, Daly ME, Kennedy EB, Antonoff MB, Broderick S, Feldman J, et al. Stereotactic body radiotherapy for early-stage non–small-cell lung cancer: American Society of Clinical Oncology endorsement of the American Society for Radiation Oncology evidence-based guideline. J Clin Oncol. Wolters Kluwer. 2018;36:710–9.

  10. Lagerwaard FJ, Verstegen NE, Haasbeek CJA, Slotman BJ, Paul MA, Smit EF, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83:348–53.

    Article  Google Scholar 

  11. Mazeron JJ, Valery CA, Boisserie G, et al. History of radiosurgery. Cancer Radiother. 2012.

  12. Ohri N. Radiotherapy dosing for locally advanced non-small cell lung carcinoma: “MTD” or “ALARA”? Front Oncol. 2017;7:205.

    Article  Google Scholar 

  13. Febbo JA, Gaddikeri RS, Shah PN. Stereotactic body radiation therapy for early-stage non–small cell lung cancer: a primer for radiologists. RadioGraphics. Radiological Society of North America. 2018;38:1312–36.

  14. Tharmalingam H, Hoskin PJ. The optimism surrounding stereotactic body radiation therapy and immunomodulation. Chin Clin Oncol. AME Publishing Company. 2017;6:2.

  15. Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys. 2019.

  16. Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16:795–803.

    Article  CAS  Google Scholar 

  17. Gupta-Burt S. Pre-Operative Immuno-Modulatory SBRT (POIMS Trial): a pilot trial in early stage NSCLC [Internet].; 2022 Mar. Report No.: NCT05094544. Available from:

  18. Prunaretty J, Boisselier P, Aillères N, Riou O, Simeon S, Bedos L, et al. Tracking, gating, free-breathing, which technique to use for lung stereotactic treatments? A dosimetric comparison. Rep Pract Oncol Radiother. 2019;24:97–104.

    Article  Google Scholar 

  19. Lagerwaard FJ, van Sornsen de Koste JR, Nijssen-Visser MR, et al. Multiple ‘slow’ CT scans for incorporating lung tumor mobility in radiotherapy planning. Int J Radiat Oncol Biol Phys. 2001.

  20. Li Y, Ma J, Chen X, Tang F, Zhang X. 4DCT and CBCT based PTV margin in stereotactic body radiotherapy(SBRT) of non-small cell lung tumor adhered to chest wall or diaphragm. Radiat Oncol. 2016;11:152.

    Article  Google Scholar 

  21. Hoffman D, Dragojević I, Hoisak J, Hoopes D, Manger R. Lung stereotactic body radiation therapy (SBRT) dose gradient and PTV volume: a retrospective multi-center analysis. Radiat Oncol. 2019;14:162.

    Article  Google Scholar 

  22. Stephans KL, Woody NM, Reddy CA, Varley M, Magnelli A, Zhuang T, et al. Tumor control and toxicity for common stereotactic body radiation therapy dose-fractionation regimens in stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2018;100:462–9.

    Article  Google Scholar 

  23. Bartl AJ, Mahoney M, Hennon MW, Yendamuri S, Videtic GMM, Stephans KL, et al. Systematic review of single-fraction stereotactic body radiation therapy for early stage non-small-cell lung cancer and lung oligometastases: how to stop worrying and love one and done. Cancers. Multidisciplinary Digital Publishing Institute. 2022;14:790.

  24. Roswell Park Cancer Institute. A pilot study of single fraction stereotactic body radiation therapy (SBRT) in central non-small cell lung cancer [Internet].; 2021 Dec. Report No.: NCT05138900. Available from:

  25. Roswell Park Cancer Institute. A feasibility and toxicity analysis of single fraction stereotactic body radiation therapy for post-operative non-small cell lung cancer [Internet].; 2022 May. Report No.: NCT04073745. Available from:

  26. Raman V, Yang C-FJ, Deng JZ, D’Amico TA. Surgical treatment for early stage non-small cell lung cancer. J Thorac Dis. 2018;10:S898–904.

    Article  Google Scholar 

  27. Zheng X, Schipper M, Kidwell K, Lin J, Reddy R, Ren Y, et al. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis. Int J Radiat Oncol. 2014;90:603–11.

    Article  Google Scholar 

  28. • Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. Elsevier. 2015;16:630–7. This reference is important because is the first prospective randomized trial comparing surgery (lobectomy) with SBRT, showing similar results of OS and LC.

  29. •• Stokes WA, Bronsert MR, Meguid RA, Blum MG, Jones BL, Koshy M, et al. Post-treatment mortality after surgery and stereotactic body radiotherapy for early-stage non–small-cell lung cancer. J Clin Oncol. Wolters Kluwer. 2018;36:642–51. This reference is of outstanding performance because it shows worrisome data of mortality after surgery in older patients.

  30. •• Chang JY, Mehran RJ, Feng L, Balter P, McRae S, Berry DA, et al. Stereotactic ablative radiotherapy in operable stage I NSCLC patients: long-term results of the expanded STARS clinical trial. J Clin Oncol. Wolters Kluwer. 2021;39:8506. This reference is of outstanding importance because it is the last published prospective trial that demonstrated the equivalence between SBRT and lobectomy for operable patients.

  31. Subramanian MP, Meyers BF. Surgical resection versus stereotactic body radiation therapy for stage I NSCLC: can randomized trials provide the solution? Cancers. Multidisciplinary Digital Publishing Institute. 2018;10:310.

  32. Louie AV, van Werkhoven E, Chen H, Smit EF, Paul MA, Widder J, et al. Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: results from the ROSEL multicenter randomized trial. Radiother Oncol. Elsevier. 2015;117:44–8.

  33. Damhuis RAM, Senan S, Khakwani A, et al. Age-related treatment patterns for stage I NSCLC in three European countries. J Geriatr Oncol. 2021.

  34. Suzuki K, Saji H, Aokage K, Watanabe S-I, Okada M, Mizusawa J, et al. Comparison of pulmonary segmentectomy and lobectomy: safety results of a randomized trial. J Thorac Cardiovasc Surg. 2019;158:895–907.

    Article  Google Scholar 

  35. Choi JI, Simone CB. Stereotactic body radiation therapy versus surgery for early stage non-small cell lung cancer: clearing a path through an evolving treatment landscape. J Thorac Dis. 2019;11:S1360–5.

    Article  Google Scholar 

  36. Takeda A, Tsurugai Y, Sanuki N. Substantial imbalance that is never eliminated with propensity score matched analyses in comparing surgery to stereotactic body radiotherapy for patients with early-stage non-small cell lung cancer. J Thorac Dis. 2019;11:S1415–9.

    Article  Google Scholar 

  37. Timmerman R. JoLT-Ca A randomized phase III study of sublobar resection (SR) versus stereotactic ablative radiotherapy (SAbR) in high risk patients with stage I non-small cell lung cancer (NSCLC), The STABLE-MATES Trial [Internet].; 2022 Jul. Report No.: NCT02468024. Available from:

  38. VA Office of Research and Development. CSP #2005 - Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy Trial (VALOR) [Internet].; 2022 Mar. Report No.: NCT02984761. Available from:

  39. •• Daly ME. Inoperable early-stage non–small-cell lung cancer: stereotactic ablative radiotherapy and rationale for systemic therapy. J Clin Oncol. Wolters Kluwer. 2022;40:539–45. This reference is of outstanding importance because it gives an overview of all trials about systemic therapy and SBRT.

  40. Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Pechoux CL, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev [Internet]. John Wiley & Sons, Ltd; 2015 [cited 2022 Jul 16]; Available from:

  41. • Wu Y-L, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med. Massachusetts Medical Society. 2020;383:1711–23. This reference is important because showed an expressive benefit of diseasefree survival in this population, what make us think that this could be the same after SBRT.

  42. • Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. Elsevier. 2021;398:1344–57. This reference is important because the combination of immunotherapy and chemotherapy after surgery has expressive benefit of disease-free survival, especially in patients whose tumors expressive PD-L1 more than 1%, what make us thing that could be reproducible after SBRT.

  43. Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol. Elsevier. 2021;22:824–35.

  44. Brown University. BrUOG 397: NEO Rad (LOW): neoadjuvant low dose stereotactic body radiotherapy, ipilimumab and nivolumab for patients with resectable stage IB - III non-small cell lung cancer [Internet].; 2022 Feb. Report No.: NCT04933903. Available from:

  45. Hong Y. Preoperative stereotactic body radiotherapy and platinum-based doublet chemotherapy plus tislelizumab (immunotherapy) for operable stage IB to III egfr wild-type non-small cell lung cancer [Internet].; 2022 May. Report No.: NCT05319574. Available from:

  46. Thompson M, Rosenzweig KE. The evolving toxicity profile of SBRT for lung cancer. Transl Lung Cancer Res [Internet]. AME Publishing Company; 2019 [cited 2022 Jul 16];8. Available from:

  47. • Yamashita H, Takahashi W, Haga A, Nakagawa K. Radiation pneumonitis after stereotactic radiation therapy for lung cancer. World J Radiol. Baishideng Publishing Group Inc. 2014;6:708–15. This reference is important because it reviews the most common toxicity of SBRT

  48. Jie Y, Gu A, Fu P, Kong F-MS. Does radiation increase the risk of immunotherapy related pneumonitis in cancer patients with thorax radiotherapy combined immune checkpoint inhibitors: a meta-analysis. J Clin Oncol. Wolters Kluwer. 2020;38:e15099.

  49. Thibault I, Chiang A, Erler D, Yeung L, Poon I, Kim A, et al. Predictors of chest wall toxicity after lung stereotactic ablative radiotherapy. Clin Oncol. Elsevier. 2016;28:28–35.

  50. Haseltine JM, Rimner A, Gelblum DY, Modh A, Rosenzweig KE, Jackson A, et al. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. Pract Radiat Oncol. 2016;6:e27–33.

    Article  Google Scholar 

  51. • Zhao Y, Khawandanh E, Thomas S, Zhang S, Dunne EM, Liu M, et al. Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors. Radiat Oncol. 2020;15:61. This reference is important because it analyze and reviews difficulties in SBRT planning of central and ultra-central tumors.

  52. Stanic S, Paulus R, Timmerman RD, Michalski JM, Barriger RB, Bezjak A, et al. No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys. Elsevier. 2014;88:1092–9.

  53. Schneider BJ, Ismaila N, Aerts J, Chiles C, Daly ME, Detterbeck FC, et al. Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline. J Clin Oncol. Wolters Kluwer. 2020;38:753–66.

  54. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines): non-small cell lung cancer. Version 1.2022. Accessed February 24, 2022. Available from:

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Lilian Faroni MD, PhD.

Ethics declarations

Conflict of Interest

Lilian Faroni declares that she has no conflict of interest. Laura Collie declares that he has no conflict of interest. Flavia Gabrielli declares that she has no conflict of interest. Clarissa Baldotto has served as a consultant/advisory board member for Astra Zeneca, Novartis, MSD, and Roche. Fabio Ynoe de Moraes (FYM) received honoraria from Astra Zeneca and IASLC outside the submitted work. FYM declares grants or contracts from CTAQ Queen’s University outside the current work. FYM has received consulting fees from Cancer em foco outside of the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Lung Cancer

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Faroni, L., Collie, L., Gabrielli, F. et al. Role of Stereotactic Radiation Therapy in Operable and Inoperable Early-Stage Non-small Cell Lung Cancer. Curr. Treat. Options in Oncol. 23, 1185–1200 (2022).

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: